Closer to class IIa HDAC inhibitors

GlaxoSmithKline plc and its Tempero Pharmaceuticals Inc. spinout have identified selective, first-in-class compounds that bind and inhibit the catalytic domain of class IIa histone deacetylases,¹ a not-so-well-understood subset of the target family that has been genetically linked to several diseases.

Both companies initially plan to study the trifluoromethyloxadiazole (TFMO) molecules in autoimmune disease...